Health & Wellness Blog - Page 42

23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss

A groundbreaking 23andMe study published in Nature identifies specific genetic changes in two genes that predict how well patients respond to GLP-1 drugs for weight loss—and whether they'll experience common side effects like nausea or vomiting. Led by Adam Auton, the research offers proof of concept for genetics in GLP-1 therapy. While experts are intrigued, questions remain on clinical impact.

Shotlee·Apr 8, 2026·4 min read

Hormone Therapy

Castle Rock Hormone Health: Redefining Longevity for High Performers

Cold plunge therapies and peptide regimens have gone mainstream among elite athletes and executives, but Castle Rock Hormone Health is elevating the game with comprehensive hormone optimization. Co-founded by Dr. Lee Moorer, the clinic targets the root causes of low energy and declining performance through advanced testing and tailored therapies. High performers are reporting clearer thinking, better sleep, and enhanced endurance.

Shotlee·Apr 8, 2026·5 min read

GLP-1 Medications

Ozempic Users Warned: Don't Skip Exercise, Study Urges

Ozempic users who skip exercise face suboptimal results, according to a new study in Sports Medicine on GLP-1 drugs like Victoza and Saxenda. Among 193 adults, those combining medication with structured workouts saw the best outcomes, while sedentary users fared worst. Meanwhile, one patient's rare blindness side effect highlights ongoing risks.

Shotlee·Apr 7, 2026·5 min read

Cardiology News

Cardiologist Sues UPMC; BP Control Stagnant; GLP-1 in Pregnancy

A prominent cardiologist has filed a whistleblower lawsuit against UPMC alleging racist texts and CEO conflicts. Meanwhile, U.S. blood pressure control remains below pre-pandemic levels, per new data. GLP-1 drugs during pregnancy show promising maternal benefits with no rise in fetal risks, according to a meta-analysis.

Shotlee·Apr 7, 2026·6 min read

Beauty & Metabolic Health

GLP-1 Beauty Boom: Ozempic Reshaping Ulta Sales & CEO Bet

GLP-1 weight-loss drugs like Ozempic are transforming beauty retail, with Ulta CEO Kecia Steelman spotting huge opportunities in 'Ozempic face' and hair thinning. Over 40 million prescriptions in 2024 signal a booming market for volumizing shampoos and firming creams. Here's how Ulta is capitalizing on this shift.

Shotlee·Apr 7, 2026·5 min read

GLP-1 Medications

Pharmacists' Key Role in Helping Patients Maximize GLP-1 Drugs

With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are emerging as crucial allies in ensuring treatment success. According to the American Society of Health-System Pharmacists, these experts help navigate costs, side effects, and lifestyle integration. This guide explores their vital role in maximizing benefits and minimizing risks.

Shotlee·Apr 7, 2026·5 min read

GLP-1 Medications

Patients Without Coverage Eagerly Await Generic Ozempic in Canada

For Canadians without drug coverage, affording Ozempic remains a major hurdle, especially for weight management beyond diabetes. Patients like 77-year-old Anne Welch watch their spouses benefit while rationing hopes on incoming generic semaglutide. With Health Canada reviewing nine submissions, relief may be near—but timelines and costs remain uncertain.

Shotlee·Apr 7, 2026·6 min read

GLP-1 Medications

Study Finds Gastrointestinal Issues Top GLP-1 Side Effects

A comprehensive review of over 1,700 clinical trials reveals gastrointestinal adverse events as the most consistent side effects of GLP-1 medications like Ozempic and Wegovy. While these drugs show potential protective effects against infections and dementia, lawsuits over stomach paralysis and vision loss are mounting. Understand the findings and what they mean for your treatment.

Shotlee·Apr 6, 2026·5 min read

GLP-1 Medications

Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains

Semaglutide injection pens command a higher price than vials primarily due to intricate manufacturing demands in sterile environments and advanced automation, as explained by OneSource Specialty Pharma CEO Neeraj Sharma. With GLP-1 drugs like semaglutide fueling a $34.5 billion market set to double by the mid-2030s, understanding these costs highlights the trade-offs for patient convenience. This guide breaks down the production process and its implications for diabetes and weight management therapies.

Shotlee·Apr 6, 2026·5 min read

Latest Articles

Latest Articles

23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss

Castle Rock Hormone Health: Redefining Longevity for High Performers

Ozempic Users Warned: Don't Skip Exercise, Study Urges

Cardiologist Sues UPMC; BP Control Stagnant; GLP-1 in Pregnancy

GLP-1 Beauty Boom: Ozempic Reshaping Ulta Sales & CEO Bet

Pharmacists' Key Role in Helping Patients Maximize GLP-1 Drugs

Patients Without Coverage Eagerly Await Generic Ozempic in Canada

Study Finds Gastrointestinal Issues Top GLP-1 Side Effects

Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains

Latest Articles

23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss

Castle Rock Hormone Health: Redefining Longevity for High Performers

Ozempic Users Warned: Don't Skip Exercise, Study Urges

Cardiologist Sues UPMC; BP Control Stagnant; GLP-1 in Pregnancy

GLP-1 Beauty Boom: Ozempic Reshaping Ulta Sales & CEO Bet

Pharmacists' Key Role in Helping Patients Maximize GLP-1 Drugs

Patients Without Coverage Eagerly Await Generic Ozempic in Canada

Study Finds Gastrointestinal Issues Top GLP-1 Side Effects

Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains